Radius Pharmaceutical, Inc. (RDUS)

Oncology Corporate Profile

Stock Performance

36.3900
1.2200

3 Month Stock History Chart

HQ Location

950 Winter St.
Waltham, MA 2451

Company Description

Radius is a science-driven biopharmaceutical company developing new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive cancers. Radius' lead development candidate is the investigational drug abaloparatide (BA058) for subcutaneous injection, currently in Phase 3 development for potential use in the reduction of fracture risk in postmenopausal women with severe osteoporosis. The Radius clinical portfolio also includes an investigational abaloparatide transdermal patch for osteoporosis and the investigational drug RAD1901 for hormone driven, or hormone resistant, metastatic breast cancer, including breast cancer brain metastases.

Website: http://www.radiuspharm.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
RAD1901SERM modulatorBreast cancerI

View additional information on product candidates here »

Source: http://www.radiuspharm.com/

Recent News Headlines

8/21/2017 06:22 am

8/21/2017 06:22 am

8/21/2017 06:22 am

8/21/2017 06:22 am

8/21/2017 06:22 am

8/18/2017 06:20 pm

8/18/2017 06:20 pm

8/18/2017 06:20 pm

8/18/2017 06:20 pm

8/18/2017 06:20 pm

8/16/2017 06:19 am

8/16/2017 06:19 am

8/16/2017 06:19 am

8/16/2017 06:19 am

8/16/2017 06:19 am

8/14/2017 06:19 am

8/14/2017 06:19 am

8/14/2017 06:19 am

8/14/2017 06:19 am

8/14/2017 06:19 am

8/8/2017 06:19 pm

8/7/2017 12:19 pm

8/7/2017 06:19 am

8/7/2017 06:19 am

8/4/2017 12:19 pm